AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer, Feb. 10, 2025
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, announced an expansion of its strategic collaboration with Eli Lilly and Company. The partnership aims to research and develop innovative treatments for various cancers.
Full Article: AdvanCell & Lilly Collaboration
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis, Feb. 10, 2025
Biodexa, a clinical-stage biopharmaceutical company developing treatments for diseases with unmet medical needs, announced that the US FDA has granted Fast Track designation for eRapa, a proprietary encapsulated form of rapamycin. The therapy is being developed for familial adenomatous polyposis (FAP), a condition with limited treatment options.
Full Article: Biodexa FDA Fast Track News
Amadix Secures €15M EIB Loan to Advance Early Cancer Detection Blood Tests, Feb. 10, 2025
The European Investment Bank (EIB) has granted a €15 million loan to Amadix, a Spanish biotech company, to support the development and commercialization of innovative blood tests for early cancer detection.
Full Article: Amadix EIB Loan News
Convergent Therapeutics Announces Positive Clinical Trial Data at ASCO GU 2025, Feb. 10, 2025
Convergent Therapeutics presented promising data at ASCO GU 2025 on its PSMA-targeted radiopharmaceutical CONV01-α (225Ac-J591). A Phase I trial combining CONV01-α with 177Lu-PSMA-I&T in advanced prostate cancer showed a median overall survival of 29.8 months, 94% PSA decline, and an 80% conversion to favorable circulating tumor cell counts. The company also highlighted its CONVERGE-01 Phase II trial, supporting further clinical development.
Full Article: Convergent Therapeutics Trial Update
Pfizer’s Prostate Cancer Candidate Shows Promising Results in Early-Stage Study, Feb. 11, 2025
A Phase 1 clinical trial of Pfizer’s prostate cancer candidate, leaked ahead of an ASCO GU 2025 presentation, showed that the drug significantly reduced the risk of disease progression when combined with hormone therapy. The full data set is expected to be presented later this week.
Full Article: Pfizer Prostate Cancer Study
Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Feb. 11, 2025
Germany’s Merck KGaA is in discussions to acquire SpringWorks Therapeutics, a biopharma company specializing in cancer and rare disease treatments. The potential deal follows SpringWorks' upcoming FDA decision on its MEK inhibitor, mirdametinib, for neurofibromatosis type 1. SpringWorks’ market cap surged by 34% after the news, exceeding $4 billion.
Full Article: Merck & SpringWorks Acquisition News
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 in Platinum-Resistant Ovarian Cancer, Feb. 12, 2025
OnCusp Therapeutics announced that the US FDA granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting Antibody-Drug Conjugate (CDH6 ADC). This designation supports the accelerated development of CUSP06 for patients with platinum-resistant ovarian cancer.
Full Article: OnCusp FDA Fast Track News
AbbVie and Xilio Sign $2.1B Immunotherapy Collaboration Deal, Feb. 12, 2025
AbbVie and Xilio Therapeutics entered into a multi-program collaboration valued at up to $2.1 billion. The deal will leverage Xilio’s tumor-activation technology alongside AbbVie’s oncology expertise to develop novel immunotherapies, including masked T-cell engagers.
Full Article: AbbVie & Xilio Partnership
Bio-Path Holdings Provides Update on BP1002 for AML Treatment, Feb. 12, 2025
Bio-Path Holdings, Inc. announced progress in its Phase 1/1b trial of BP1002 for venetoclax-resistant acute myeloid leukemia (AML), showing meaningful patient responses, including stable disease and significant blast count reduction after one treatment cycle. The trial has advanced to the fourth cohort with a higher dose of 90 mg/m². BP1002, targeting Bcl-2 at the mRNA level, offers potential for patients resistant to venetoclax therapy. The study is conducted at U.S. cancer centers, with combination therapy planned in the next phase.
Full Article: Bio-Path Holdings Update
Xilio Therapeutics Announces New Masked T Cell Engager Programs, Feb. 12, 2025
Xilio Therapeutics, Inc. revealed three preclinical masked T cell engager programs targeting PSMA, CLDN18.2, and STEAP1, alongside a collaboration with AbbVie to develop tumor-activated immunotherapies. The collaboration includes a $52 million upfront payment and additional milestone payments. Xilio’s tumor-activation technology aims to enhance T cell engager efficacy by activating them selectively in tumors.
Full Article: Xilio Therapeutics Collaboration
Abcuro Closes $200M Series C Financing, Feb. 13, 2025
Abcuro, Inc. announced the closing of a $200M Series C financing led by NEA and Foresite Capital. The funds will support the Phase 2/3 MUSCLE trial of ulviprubart (ABC008), a KLRG1-targeting monoclonal antibody for inclusion body myositis (IBM). Initial data is expected in 1H 2026, and the company plans to file for a BLA and prepare for commercial launch.
Full Article: Abcuro Series C Financing
IDEAYA Biosciences Expands Collaboration with Gilead Science, Feb. 13, 2025
IDEAYA Biosciences, Inc. has entered a clinical study collaboration with Gilead Sciences to evaluate IDE397, a MAT2A inhibitor, in combination with Trodelvy for MTAP-deletion non-small cell lung cancer (NSCLC). The ongoing Phase 1 trial, originally focused on urothelial cancer, will now include MTAP-deletion NSCLC patients. This collaboration aims to explore a potential first-in-class combination therapy for MTAP-deletion solid tumors.
Full Article: IDEAYA Biosciences Collaboration
